Oral intake of Kluyveromyces marxianus B0399 plus Lactobacillus rhamnosus CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial

Navarro-López, Vicente; Hernández-Belmonte, Adriana; Soto, Maria Isabel Pérez; Ayo-González, Maikel; Losa-Rodríguez, Guillermo; Ros-Sánchez, Esther; Martínez-Gabarrón, Maravillas; Sánchez-Pellicer, Pedro; Agüera-Santos, Juan; Núñez‐Delegido, Eva; Ruzafa-Costas, Beatriz; Picó-Monllor, José Antonio; Navarro-Moratalla, Laura

doi:10.1016/j.medmic.2022.100061

Cited by 16 publications

(25 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,14,30 A latest study revealed that the oral intake of a K. marxianus B0399 and Lactobacillus rhamnosus CECT 30579 mixture mitigated symptoms in COVID-19 patients. 16 Our study indicated that K. marxianus treatment in vivo for 3 weeks reversed the loss of weight, elevated liver index and liver steatosis in ALD mice. Moreover, K. marxianus supplementation reduced the leakage of ALT and AST and alleviated liver injury induced by alcohol.…”

Section: Discussionmentioning

confidence: 51%

“…† Based on previous research, ethanol-fed mice were treated with K. marxianus (2 × 10 8 CFU), whereas control mice were treated with an equivalent volume (200 µL) of PBS. 14,16,20 The dosage for mice was about 4 × 10 6 CFU per kg body weight, which is equivalent to 2.16 × 10 9 CFU (3.6 × 10 7 CFU kg −1 ) in adult humans (60 kg). It is achievable by consuming commercial dairy products, such as kefir.…”

Section: Animal Experimentationmentioning

confidence: 99%

“…15 Unexpectedly, a recent report has demonstrated the effect of K. marxianus B0399 supplementation on COVID-19 patients, with promising results. 16 It has been reported that K. marxianus has high gamma-aminobutyric acid (GABA) production via the decarboxylation reaction catalyzed by glutamate decarboxylase. 17 GABA is a non-protein amino acid that has been shown to relieve hypertension and improve diabetes.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Kluyveromyces marxianus supplementation ameliorates alcohol-induced liver injury associated with the modulation of gut microbiota in mice

Cui,

Guo,

Ning

et al. 2023

Food Funct.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 51%

Section: Animal Experimentationmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Kluyveromyces marxianus supplementation ameliorates alcohol-induced liver injury associated with the modulation of gut microbiota in mice

Cui,

Guo,

Ning

et al. 2023

Food Funct.

View full text Add to dashboard Cite

show abstract

“…Three studies ( 23 , 26 , 27 ) reported the number of people with overall symptom improvement after treatment. The average improvement rate was 59.2% in the probiotics group and 37.7% in the non-probiotics group.…”

Section: Resultsmentioning

confidence: 99%

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

et al. 2023

View full text Add to dashboard Cite

BackgroundMulti system symptoms such as gastrointestinal tract and respiratory tract exist in coronavirus disease 2019 (COVID-19) patients. There is a lack of reliable evidence to prove that probiotics are effective in improving these symptoms. In this study, we aimed to evaluate the efficacy of probiotics in meta-analysis.MethodsWe systematically searched PubMed, Embase, Web of Science, and Cochrane Library up to February 15, 2023. Randomized controlled trials or high quality retrospective studies comparing the efficacy of probiotics as supplementation with non-probiotics in improving symptoms for patients with COVID-19 were included. This meta-analysis assessed endpoints using Review Manager 5.3.ResultTen citations comprising 1198 patients with COVID-19 were included. The results showed that probiotics could increase the number of people with overall symptom improvement (RR = 1.62, 95% CI [1.10, 2.38], P = 0.01) and shorten the duration (days) of overall symptoms (MD = −1.26, 95% CI [−2.36, −0.16], P = 0.02). For the duration (days) of specific symptoms, probiotics could improve diarrhea (MD = −2.12, 95% CI [−2.41, −1.83], P < 0.00001), cough (MD = −2.21, 95% CI [-4.56, 0.13], P = 0.06) and shortness of breath (MD = −1.37, 95% CI [-2.22, −0.53], P = 0.001). Probiotics had no obvious effect on fever, headache and weakness. For inflammation, probiotics could effectively reduce C-reactive Protein (CRP) serum level (mg/L) (MD = −4.03, 95% CI [−5.12, −2.93], P < 0.00001). Regarding hospital stay (days), probiotics group was shorter than non-probiotics group (MD = −0.98, 95% CI [−1.95, −0.01], P = 0.05).ConclusionTo some extent probiotics could improve the overall symptoms, inflammatory reaction and shorten hospital stay of patients with COVID-19. Probiotics may improve gastrointestinal symptoms (such as improving intestinal flora and reducing the duration of diarrhea) and further improve respiratory symptoms through the gut-lung axis.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=398309, identifier: CRD42023398309.

show abstract

“…Kluyveromyces marxianus exhibits potential probiotic characters by improving immune response and human gut microbiota in an in vitro colonic model system [5]. Oral intake of K. marxianus and Lactobacillus species was found to mitigate symptoms by reducing the cases of gastrointestinal pyrosis and abdominal pain and musculoskeletal pain in COVID-19 patients [6]. The fermented milk containing K. marxianus and Bifidobacterium lactis alleviated symptoms (abdominal pain, bloating, and bowel movement disturbances) in irritable bowel syndrome (IBS) patients [7].…”

Section: Introductionmentioning

confidence: 99%

Kluyveromyces marxianus Ameliorates High-Fat-Diet-Induced Kidney Injury by Affecting Gut Microbiota and TLR4/NF-κB Pathway in a Mouse Model

Zhao

2023

Cellular Microbiology

View full text Add to dashboard Cite

Objectives. The effects of Kluyveromyces marxianus on high-fat diet- (HFD-) induced kidney injury (KI) were explored. Methods. HFD-induced KI model was established using male C57BL/6 mice and treated with K. marxianus JLU-1016 and acid-resistant (AR) strain JLU-1016A. Glucose tolerance was evaluated via an oral glucose tolerance test (OGTT). KI was measured using Hematoxylin and Eosin (H&E) staining and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) analysis. The chemical indexes were analyzed, including lipid profiles, inflammatory cytokines, and creatinine. The levels of Toll-like receptor 4 (TLR4)/nuclear factor kappa B (NF-κB) or phospho-NF-κB p65 (Ser536) and alpha inhibitor of NF-κB (IκBα) were measured using qPCR and Western blot. The gut microbiota was sequenced using high-throughput sequencing. Results. HFD induction increased OGTT value, KI severity, oxidative stress, inflammatory cytokines, oxidative stress, apoptotic rate, creatinine levels, and the expression of TLR4/NF-κB, phospho-NF-κB p65 (Ser536), and IκBα deteriorated lipid profiles ( P < 0.05 ) and reduced gut microbiota abundance. K. marxianus treatment ameliorated HFD-induced metabolic disorders and reversed these parameters ( P < 0.05 ). Compared with the control, HFD induction increased the proportion of Firmicutes but reduced the proportion of Bacteroidetes and Lactobacillus. K. marxianus JLU-1016 and AR strain JLU-1016A treatments improved gut microbiota by reducing the proportion of Firmicutes and increasing the proportion of Bacteroidetes and Lactobacillus in the KI model ( P < 0.0001 ). Helicobacter has been identified with many infectious diseases and was increased after HFD induction and inhibited after K. marxianus JLU-1016 and AR strain JLU-1016A treatments. The strain JLU-1016A exhibited better results possibly with acid-tolerance properties to pass through an acidic environment of the stomach. Conclusions. K. marxianus may have a beneficial effect on KI by improving gut microbiota and inhibiting TLR4/NF-κB pathway activation.

show abstract

Oral intake of Kluyveromyces marxianus B0399 plus Lactobacillus rhamnosus CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial

Cited by 16 publications

References 31 publications

Kluyveromyces marxianus supplementation ameliorates alcohol-induced liver injury associated with the modulation of gut microbiota in mice

Kluyveromyces marxianus supplementation ameliorates alcohol-induced liver injury associated with the modulation of gut microbiota in mice

Probiotics improve symptoms of patients with COVID-19 through gut-lung axis: a systematic review and meta-analysis

Kluyveromyces marxianus Ameliorates High-Fat-Diet-Induced Kidney Injury by Affecting Gut Microbiota and TLR4/NF-κB Pathway in a Mouse Model

Contact Info

Product

Resources

About